SNTI Profile
Senti Biosciences, Inc. is a pioneering preclinical biotechnology firm specializing in the development of advanced cell and gene therapies through its innovative gene circuit platform technologies.
The company's core approach involves engineering next-generation therapies that harness the potential of gene circuits to precisely target and treat a range of diseases. Senti Biosciences focuses primarily on oncology, utilizing its expertise to create cutting-edge therapeutic solutions that aim to transform cancer treatment.
The company’s lead product candidates are based on allogeneic chimeric antigen receptor natural killer (CAR-NK) cells integrated with its proprietary gene circuit technologies. These advanced therapies are designed to improve the efficacy and safety profiles of cancer treatments. Key product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy specifically engineered to target and destroy acute myeloid leukemia (AML) cells while preserving healthy bone marrow. This precision approach aims to minimize collateral damage to non-cancerous tissues.
Senti Biosciences is also developing SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy intended for the treatment of hepatocellular carcinoma (HCC). This therapy is designed to effectively target cancer cells in the liver while sparing healthy cells, enhancing the overall safety and therapeutic impact. Additionally, SENTI-401 is a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy that targets and eliminates colorectal cancer cells with high specificity, aiming to avoid harm to normal tissues and reduce adverse effects.
Incorporated in 2016 and headquartered in South San Francisco, California, Senti Biosciences has rapidly established itself as a leader in the biotechnology sector. The company's cutting-edge gene circuit platform and focus on CAR-NK cell therapies position it at the forefront of the industry, with the potential to significantly advance the treatment landscape for various types of cancer.
|
